Brief: Sorrento Therapeutics Says China's National Medical Products Administration Clears Lee's Pharmaceutical To Conduct Phase III Trial Of Socazolimab

Lees Pharmaceutical Holdings

08/03/2021 03:35

March 7 (Reuters) - Sorrento Therapeutics Inc  SRNE.O :
    * LEE’S PHARMACEUTICAL ANNOUNCES ITS ANTI-PD-L1 ANTIBODY
SOCAZOLIMAB, LICENSED FROM SORRENTO THERAPEUTICS, RECEIVES
CLEARANCE TO START PHASE 3 TRIAL AS A FIRST-LINE TREATMENT OF
EXTENSIVE-STAGE SMALL-CELL LUNG CANCER
    * CHINA'S NATIONAL MEDICAL PRODUCTS ADMINISTRATION CLEARS
LEE'S
PHARM TO CONDUCT A PHASE III TRIAL OF SOCAZOLIMAB
    * SHANGHAI CHEST HOSPITAL IS EXPECTED TO INITIATE PATIENT
RECRUITMENT IN Q2
    * LEE'S PHARM EXPECTS TO FILE NEW DRUG APPLICATION FOR
SOCAZOLIMAB
IN RECURRENT OR METASTATIC CERVICAL CANCER IN Q2

Source text for Eikon:  ID:nGNX8vTCRp 
Further company coverage:  SRNE.O 

 ((Reuters.Briefs@thomsonreuters.com;))